coadministered cagrilintide and semaglutide in adults with overweight or obesity Summary of REDEFINE 1 REDEFINE 2 trials CagriSema, presented this week at #ADA2025 and published NEJM: REDEFINE 1: • 👥 3,417 participants with (without diabetes) treated https://t.co/JjeCTJQPXH Cagrilintide–Semaglutide in Adults with

[1] [2] Anesthesiologists may employ risk mitigation strategies including rapid sequence induction, cricoid pressure, use of medications to reduce gastric acidity (proton pump inhibitors, H2-blockers), and consideration of point-of-care gastric ultrasound to assess residual gastric volume

Obesity is not listed as a chronic PMB condition, and its not included under any of the 271 medical emergencies or 26 chronic diseases

These GI effects overlap with tirzepatide common side effects, which raises a legitimate concern

Safety of glucagon-like peptide-1 receptor agonists: a real-world study based on the us FDA adverse event reporting system database